These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7109641)

  • 1. Effects of diethylstilbestrol diphosphate on serum and tissue ribonuclease levels in prostatic carcinoma.
    Erkan I; Ciliv G; Remzi D
    J Surg Oncol; 1982 Sep; 21(1):65-9. PubMed ID: 7109641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the cytotoxic activity of diethylstilbestrol and its mono- and diphosphate towards prostatic carcinoma cells.
    Schulz P; Bauer HW; Brade WP; Keller A; Fittler F
    Cancer Res; 1988 May; 48(10):2867-70. PubMed ID: 2834049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme markers in human prostatic carcinoma.
    Chu TM; Wang MC; Kuciel R; Valenzuela L; Murphy GP
    Cancer Treat Rep; 1977; 61(2):193-200. PubMed ID: 68822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme immunoassay of prostatic acid phosphatase after prostatic examination. Correlation with prostate size and immunopathology.
    el-Shirbiny AM; Shridhar P; al Adnani MS; Suresh LK
    Urology; 1988 Nov; 32(5):469-73. PubMed ID: 2460989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of serum prostatic acid phosphatase levels after prostatic massage.
    Wadström J; Huber P; Rutishauser G
    Urology; 1984 Dec; 24(6):550-1. PubMed ID: 6209846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells.
    Robertson CN; Roberson KM; Padilla GM; O'Brien ET; Cook JM; Kim CS; Fine RL
    J Natl Cancer Inst; 1996 Jul; 88(13):908-17. PubMed ID: 8656443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of diethylstilbestrol diphosphate on activity of 5 alpha-reductase in human prostate.
    Usui T; Ishibe T; Nakamura K; Mizutani M; Yasukawa A
    Arch Androl; 1987; 19(3):229-35. PubMed ID: 2461177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Decrease in anticoagulant factors in patients with prostate cancer treated with diethylstilbestrol diphosphate].
    Hayashi N; Wada T; Ikemoto I; Oishi Y; Suzuki H; Ueda M
    Nihon Hinyokika Gakkai Zasshi; 2003 Mar; 94(3):420-7. PubMed ID: 12710076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
    Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
    Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of prostate-specific antigen and prostatic acid phosphatase concentrations in serum before and 1-42 days after transurethral resection of the prostate and orchidectomy.
    Price A; Attwood SE; Grant JB; Gray TA; Moore KT
    Clin Chem; 1991 Jun; 37(6):859-63. PubMed ID: 1710953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the mitochondrial bc1-complex in the cytotoxic action of diethylstilbestrol-diphosphate toward prostatic carcinoma cells.
    Schulz P; Link TA; Chaudhuri L; Fittler F
    Cancer Res; 1990 Aug; 50(16):5008-12. PubMed ID: 2165852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue acid and alkaline phosphatase in prostatic carcinoma.
    Erkan I; Remzi D; Ciliv G
    J Surg Oncol; 1980; 13(4):341-5. PubMed ID: 6154841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change of total and prostatic serum acid phosphatase levels following hyperglycemic treatment in patients with prostatic carcinoma.
    Ishibe T
    Urol Int; 1980; 35(1):13-9. PubMed ID: 7361348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical assessment of solid phase immunoadsorbent assay of human prostatic acid phosphatase.
    Bauer HW; Schmeller NT
    Urology; 1984 Mar; 23(3):247-51. PubMed ID: 6199879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of prostatic cancer by an enzyme-linked immunosorbent assay of serum prostatic acid phosphatase.
    Cooper EH; Pidcock NB; Daponte D; Glashan RW; Rowe E; Robinson MR
    Eur Urol; 1983; 9(1):17-23. PubMed ID: 6337053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum acid phosphatase in patients with localised prostatic cancer, benign prostatic hyperplasia or normal prostates.
    Salo JO; Rannikko S; Haapiainen R
    Br J Urol; 1990 Aug; 66(2):188-92. PubMed ID: 1697205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian and day-to-day variation of prostatic acid phosphatase.
    Nissenkorn I; Mickey DD; Miller DB; Soloway MS
    J Urol; 1982 Jun; 127(6):1122-4. PubMed ID: 6177878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic usefulness of serum acid phosphatase levels in carcinoma of the prostate.
    Ishibe T; Usui T; Nihira H
    J Urol; 1974 Aug; 112(2):237-40. PubMed ID: 4843340
    [No Abstract]   [Full Text] [Related]  

  • 19. Carcinoma of the prostate. II. Serum activity of acid phosphatase, prostatic acid phosphatase, LDH and its isoenzymes.
    Mráz J; Vrubel F; Hanselová M
    Int Urol Nephrol; 1979; 11(4):301-9. PubMed ID: 536179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
    Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.